Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 8, 2005
app pub date -
Apr 27, 2005
filing date -
Jul 4, 2002
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention relates to neuroreceptor active N-[(4-phenyl-1-piperazinyl)a-lkyl]-substituted heteroarene carboxamide of general formula (I) and to structure analogous 2-ferrocenyl compounds of general formula (II) and the utilization thereof for the treatment of CNS diseases, for example, schizophrenia, different forms of depression, neurodegenerative disorders, sexual dysfunctions, cocaine, alcohol, opiate and nicotine addiction, in addition to glaucoma, cognitive disorders, restless leg syndrome, hyperactivity syndrome (ADHS), hyperprolactinemia, hyperprolactinoma, locomotion disorders associated with Parkinson's disease, treatment of L-DOPA and neuroleptic-induced locomotion disorders, for example, akathisia, rigor, dystonia and dyskinesia, wherein the substituents are defined in the description. 1
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully